Stock listing
Stuttgart:RI2 Rigel Pharmaceuticals, Inc. Aktie
German listing (Stuttgart) of Rigel Pharmaceuticals, Inc. · home listing NASDAQ:RIGL
Follow Rigel Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:RIGL
$40.09 USD -2.44 (-5.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RIGL
- Day range
- $39.62 – $41.66 USDNov 20, 2026
- Volume
- 352,028 sharesNov 20, 2026
- Market cap
- $754.9M USDAt the close on Nov 20, 2026 · price × 18.83M shares outstanding
- 52-week range
- $24.95 – $52.61 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $11.64M USDMedian day 210,027 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RIGL · Home | $40.09 USD | -2.44 (-5.7%) | 352,028 | $40.65 | $41.66 | $39.62 | $42.53 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RIGL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $40.09 | -2.44 | -5.7% | $40.65 | $41.66 | $39.62 | 352,028 | |
| $42.53 | -0.39 | -0.9% | $42.79 | $43.88 | $42.03 | 304,827 | |
| $42.92 | -0.81 | -1.9% | $43.43 | $43.48 | $42.10 | 242,198 | |
| $43.73 | -0.73 | -1.6% | $44.95 | $45.70 | $43.42 | 148,594 | |
| $44.46 | -1.23 | -2.7% | $45.94 | $45.94 | $43.84 | 151,587 | |
| $45.69 | +1.17 | +2.6% | $44.21 | $46.21 | $43.44 | 325,687 | |
| $44.52 | +0.61 | +1.4% | $44.00 | $44.63 | $43.48 | 140,664 | |
| $43.91 | +1.86 | +4.4% | $42.15 | $44.14 | $41.91 | 249,582 | |
| $42.05 | +2.40 | +6.1% | $40.39 | $42.16 | $39.50 | 310,276 | |
| $39.65 | -6.06 | -13.3% | $41.11 | $41.67 | $37.60 | 759,086 | |
| $45.71 | -5.58 | -10.9% | $51.53 | $51.53 | $44.99 | 550,900 | |
| $51.29 | +2.43 | +5.0% | $50.57 | $51.74 | $49.23 | 288,610 | |
| $48.86 | -1.67 | -3.3% | $50.44 | $51.29 | $46.88 | 286,974 | |
| $50.53 | -0.78 | -1.5% | $51.33 | $51.84 | $50.00 | 136,045 | |
| $51.31 | -0.14 | -0.3% | $51.80 | $52.61 | $50.67 | 174,404 | |
| $51.45 | +0.71 | +1.4% | $51.17 | $51.60 | $50.24 | 159,468 | |
| $50.74 | +0.19 | +0.4% | $50.26 | $51.36 | $50.06 | 226,326 | |
| $50.55 | +0.64 | +1.3% | $50.09 | $50.70 | $49.54 | 133,103 | |
| $49.91 | +1.78 | +3.7% | $48.63 | $50.00 | $48.32 | 196,514 | |
| $48.13 | -0.73 | -1.5% | $48.48 | $48.48 | $47.47 | 119,260 | |
| $48.86 | -0.02 | 0.0% | $48.97 | $49.94 | $48.55 | 152,640 | |
| $48.88 | +0.77 | +1.6% | $47.64 | $49.01 | $47.64 | 195,892 | |
| $48.11 | +1.39 | +3.0% | $46.73 | $48.16 | $46.73 | 366,263 | |
| $46.72 | +0.75 | +1.6% | $46.39 | $47.39 | $45.48 | 318,414 | |
| $45.97 | -1.28 | -2.7% | $47.58 | $47.58 | $45.68 | 141,432 | |
| $47.25 | +0.43 | +0.9% | $47.01 | $48.52 | $47.01 | 167,854 | |
| $46.82 | -0.32 | -0.7% | $46.82 | $47.99 | $46.37 | 160,104 | |
| $47.14 | -1.67 | -3.4% | $48.70 | $48.87 | $47.04 | 133,999 | |
| $48.81 | -0.27 | -0.6% | $49.22 | $49.89 | $48.54 | 162,529 | |
| $49.08 | +0.36 | +0.7% | $48.60 | $50.49 | $48.60 | 279,362 | |
| $48.72 | +0.73 | +1.5% | $47.33 | $48.89 | $46.56 | 216,848 | |
| $47.99 | +1.88 | +4.1% | $45.64 | $48.15 | $45.22 | 232,584 | |
| $46.11 | -1.68 | -3.5% | $48.18 | $48.18 | $45.93 | 202,598 | |
| $47.79 | +0.64 | +1.4% | $47.02 | $48.83 | $46.93 | 391,628 | |
| $47.15 | +0.18 | +0.4% | $47.66 | $48.00 | $46.45 | 185,673 | |
| $46.97 | -1.18 | -2.5% | $48.05 | $48.87 | $46.81 | 234,998 | |
| $48.15 | -0.74 | -1.5% | $49.27 | $49.70 | $47.80 | 252,210 | |
| $48.89 | -0.47 | -1.0% | $49.38 | $49.70 | $48.61 | 182,255 | |
| $49.36 | +1.18 | +2.4% | $48.16 | $49.65 | $47.49 | 180,879 | |
| $48.18 | +0.29 | +0.6% | $48.23 | $48.53 | $47.20 | 204,930 | |
| $47.89 | -0.24 | -0.5% | $47.87 | $48.14 | $47.00 | 143,824 | |
| $48.13 | -0.69 | -1.4% | $48.62 | $48.69 | $46.91 | 151,375 | |
| $48.82 | +1.73 | +3.7% | $47.50 | $49.02 | $47.23 | 242,877 | |
| $47.09 | +0.45 | +1.0% | $47.13 | $47.51 | $46.49 | 164,839 | |
| $46.64 | +0.79 | +1.7% | $45.54 | $46.99 | $45.24 | 939,569 | |
| $45.85 | +1.37 | +3.1% | $45.25 | $46.27 | $45.14 | 165,748 | |
| $44.48 | +0.12 | +0.3% | $44.14 | $45.37 | $43.78 | 226,406 | |
| $44.36 | -0.99 | -2.2% | $45.14 | $46.26 | $44.22 | 269,889 | |
| $45.35 | -1.89 | -4.0% | $47.32 | $47.53 | $44.96 | 335,807 | |
| $47.24 | -0.04 | -0.1% | $47.84 | $47.86 | $47.00 | 187,183 | |
| $47.28 | +0.06 | +0.1% | $46.69 | $47.35 | $46.28 | 131,329 | |
| $47.22 | -0.15 | -0.3% | $46.85 | $47.88 | $46.78 | 177,148 | |
| $47.37 | -1.30 | -2.7% | $48.09 | $48.11 | $46.61 | 248,396 | |
| $48.67 | +0.17 | +0.4% | $48.04 | $48.87 | $47.77 | 104,968 | |
| $48.50 | -0.92 | -1.9% | $49.51 | $49.90 | $48.09 | 190,389 | |
| $49.42 | +1.92 | +4.0% | $48.00 | $49.70 | $47.73 | 184,699 | |
| $47.50 | +1.32 | +2.9% | $46.15 | $47.85 | $46.15 | 205,505 | |
| $46.18 | -0.30 | -0.6% | $46.04 | $46.59 | $45.31 | 243,090 | |
| $46.48 | -0.38 | -0.8% | $46.46 | $46.79 | $45.68 | 246,125 | |
| $46.86 | +0.38 | +0.8% | $46.29 | $47.00 | $45.61 | 210,027 | |
| $46.48 | -0.27 | -0.6% | $46.34 | $47.09 | $45.37 | 232,250 | |
| $46.75 | +1.64 | +3.6% | $45.48 | $47.46 | $45.14 | 373,973 | |
| $45.11 | -0.78 | -1.7% | $45.63 | $46.21 | $44.51 | 542,005 | |
| $45.89 | +0.64 | +1.4% | $45.74 | $46.49 | $45.00 | 322,086 | |
| $45.25 | -1.71 | -3.6% | $46.24 | $47.34 | $44.80 | 417,413 |
Splits
2 splits since 2003 · NASDAQ:RIGL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-9 | Consolidation |
- Ticker
- Stuttgart:RI2
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Rigel to Present at the Jefferies Global Healthcare Conference in London
Latest earnings call · Nov 5, 2026
Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 5, 2026
Investor Presentation (November 2026)
Investor deck · 65 slides
Latest news
Rigel to Present at the Jefferies Global Healthcare Conference in London
Nov 10, 2026
Closed $43.91 (+4.4%) on Nov 10, 2026
Quarterly Report for Quarter Ending SEPTEMBER 30, 2026 (Form 10-Q)
Nov 5, 2026
Closed $39.65 (-13.3%) on Nov 6, 2026
Rigel Reports Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $39.65 (-13.3%) on Nov 6, 2026
Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition
Nov 4, 2026
Closed $51.29 (+5.0%) on Nov 4, 2026
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
Oct 29, 2026
Closed $51.45 (+1.4%) on Oct 29, 2026
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Oct 19, 2026
Closed $46.72 (+1.6%) on Oct 19, 2026
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 2, 2026
Closed $47.15 (+0.4%) on Oct 2, 2026
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Aug 11, 2026
Closed $42.02 (+0.9%) on Aug 11, 2026
Rigel Reports Second Quarter 2026 Financial Results
Aug 4, 2026
Closed $40.48 (+4.6%) on Aug 5, 2026
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Jul 28, 2026
Closed $38.50 (+3.0%) on Jul 28, 2026
Rigel Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 145 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 21 calls with a replay · 21 with a transcript · latest Nov 5, 2026
- Decks
- 17 decks · latest Nov 5, 2026
Where Rigel Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RIGL · Home listing | NASDAQ | United States | USD |
| LS Exchange:A40EFY | LS Exchange | Germany | EUR |
| Lang & Schwarz:A40EFY | Lang & Schwarz | Germany | EUR |
| gettex:RI2 | gettex | Germany | EUR |
| Tradegate:RI2 | Tradegate | Germany | EUR |
| BX Swiss:RIGL | BX Swiss | Switzerland | CHF |
| BOATS:RIGL | BOATS | United States | USD |
| Dusseldorf:RI2 | Dusseldorf | Germany | EUR |
| Frankfurt:RI2 | Frankfurt | Germany | EUR |
| Munich:RI2 | Munich | Germany | EUR |
| Stuttgart:RI2 · This page | Stuttgart | Germany | EUR |
Valuation
P/E 2.5× against a median of 11.4×: the lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $663.4M USD
- P/E
- 2.5×
- EV/sales
- 2.3×
- EV/EBITDA
- 8.3×
- Price/book
- 1.7×
- Gross margin
- 89.6%
- Operating margin
- 26.3%
- Net margin
- 106.6%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.02
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals, Inc. · NASDAQ:RIGL | US$754.9M | US$663.4M | 2.5× | 2.3× | 8.3× | 1.7× | 106.6% | 0.0× | 1.02 |
| Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595 | US$787.5M | US$518.8M | n/a | 26.5× | n/a | 3.3× | n/a | 0.0× | n/a |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335 | US$778.7M | US$599.6M | n/a | n/a | n/a | 5.5× | n/a | 0.0× | n/a |
| Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD | US$778.1M | US$702.9M | 5.2× | 1.8× | n/a | n/a | 37.4% | n/a | 1.16 |
| Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX | US$772.7M | US$695.6M | n/a | 2.4× | n/a | n/a | −72.4% | n/a | 0.64 |
| MeiraGTx Holdings plc · NASDAQ:MGTX | US$766.4M | US$715.6M | 9.8× | 1.8× | 3.7× | 3.6× | 19.5% | 0.6× | 1.57 |
| ORIC Pharmaceuticals, Inc. · NASDAQ:ORIC | US$764.9M | US$503.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.22 |
| Inventiva SA · EURONEXT:IVA | US$760.9M | US$577.3M | n/a | 117× | n/a | 11.8× | n/a | 1.1× | n/a |
| Obsidian Therapeutics, Inc. · NASDAQ:OBX | US$741.3M | US$530.4M | 13.0× | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE | US$738.3M | US$196.8M | n/a | 2.8× | n/a | 1.5× | −186.2% | 0.1× | 0.92 |
| Aimed Bio Inc. · KRX:0009K0 | US$722.1M | US$653.2M | 25.2× | 13.2× | 34.0× | 4.8× | 57.8% | 0.0× | n/a |
| Median of the others | US$765.7M | US$588.5M | 11.4× | 2.8× | 18.9× | 3.4× | 19.5% | 0.0× | 1.16 |
Forecasts
2 strong buy · 2 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 64.40 USD · Analysts' mean
- EPS, year to Dec 2026
- 3.34 · 4 analysts
- Revenue, year to Dec 2026
- 309.9M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Raul R. Rodriguez | President and Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Gregg A. Lapointe | Director |
| Jane Wasman | Director |
| Kamil Ali-Jackson | Director |
| Mark W. Frohlich | Director |
| Michael P. Miller | Director |
| Raul R. Rodriguez | President and Chief Executive Officer |
| Walter H. Moos | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| Rigel Pharmaceuticals (NASDAQ:RIGL) Q2 2026 Earnings Call | Tue, Aug 04, 2026 · 4:30 PM ET | Replay |
| Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2026 Earnings Call | Tue, May 05, 2026 · 4:30 PM ET | Replay |
| Rigel Pharmaceuticals (NASDAQ:RIGL) Q4 2025 Earnings Call | Tue, Mar 03, 2026 · 4:30 PM ET | Replay |
| Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2025 Earnings Call | Tue, Nov 04, 2025 · 4:30 PM ET | Replay |
| Rigel Pharmaceuticals (NASDAQ:RIGL) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 4:30 PM ET | Replay |
| Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2025 Earnings Call | Tue, May 06, 2025 · 4:30 PM ET | Replay |
| Rigel Pharmaceuticals (NASDAQ:RIGL) Q4 2024 Earnings Call | Tue, Feb 04, 2025 · 4:30 PM ET | Replay |
| Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:30 PM ET | Replay |
| Rigel Pharmaceuticals (NASDAQ:RIGL) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 4:30 PM ET | Replay |
All 21 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −13.3% |
| Q2 2026 | Aug 4, 2026 · After close | +4.6% |
| Q1 2026 | May 5, 2026 · After close | −5.1% |
| Q4 2025 | Mar 4, 2026 | −10.6% |
| Q3 2025 | Nov 4, 2025 · After close | +33.4% |
| Q2 2025 | Aug 5, 2025 · After close | +23.0% |
| Q1 2025 | May 6, 2025 · After close | +1.1% |
| Q4 2024 | Mar 4, 2025 · After close | −8.1% |
| Q3 2024 | Nov 7, 2024 · After close | +42.9% |
| Q2 2024 | Aug 6, 2024 · After close | +5.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −16.6% |
| Q4 2023 | Mar 5, 2024 · After close | +5.4% |
| Q3 2023 | Nov 7, 2023 · After close | +2.2% |
| Q2 2023 | Aug 1, 2023 · After close | −3.0% |
| Q1 2023 | May 2, 2023 · After close | +0.9% |
| Q4 2022 | Mar 7, 2023 · After close | +21.8% |
| Q3 2022 | Nov 3, 2022 · After close | +2.0% |
| Q2 2022 | Aug 2, 2022 · After close | +8.5% |
| Q1 2022 | May 3, 2022 · After close | +6.5% |
| Q4 2021 | Mar 1, 2022 · After close | +21.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 65 slides | Nov 5, 2026 |
| H.C. Wainwright 28th Annual Global Investment Conference (September 2026) | Conference | 40 slides | Sep 15, 2026 |
| Cantor Global Healthcare Conference 2026 | Conference | 40 slides | Sep 10, 2026 |
| Investor Presentation (August 2026) | Investor deck | 72 slides | Aug 13, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 45 slides | Aug 4, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 73 slides | Aug 4, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 51 slides | May 5, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 54 slides | Mar 3, 2026 |
| Q1 2025 Earnings Presentation | Earnings | 38 slides | May 6, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 40 slides | Feb 4, 2025 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2024 Earnings Presentation | Earnings | 37 slides | Nov 7, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 38 slides | Aug 6, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 43 slides | May 7, 2024 |
| Q4 2023 Earnings Presentation | Earnings | 37 slides | Mar 5, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 30 slides | Nov 7, 2023 |
| Technical Presentation (October 2016) | Technical | 26 slides | Oct 20, 2016 |
| Technical Presentation (December 2007) | Technical | 9 slides | Dec 4, 2007 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 294.3M | 179.3M | 116.9M | 120.2M | 149.2M | 108.6M | 59.3M | 44.5M | 4.48M | 20.4M |
| Cost of revenue | 19.6M | 18.6M | 7.11M | 1.75M | 1.08M | 895.0K | 906.0K | 287.0K | 46.3M | 63.4M |
| Gross profit | 274.7M | 160.6M | 109.8M | 118.5M | 148.2M | 107.7M | 58.4M | 44.2M | -41.8M | -43.1M |
| Research and development | 33.3M | 23.4M | 24.5M | 60.3M | 65.2M | 60.1M | 52.9M | 46.9M | 46.3M | 63.4M |
| Selling, general and administrative | 115.9M | 113.1M | 105.7M | 112.5M | 91.9M | 76.6M | 74.6M | 70.0M | 37.8M | 20.9M |
| Operating income | 125.5M | 24.2M | -20.5M | -55.5M | -12.5M | -29.0M | -69.1M | -72.7M | -79.6M | -69.7M |
| Depreciation and amortization | 2.42M | 2.23M | 1.24M | 998.0K | 1.16M | 706.0K | 683.0K | 594.0K | 465.0K | 941.0K |
| EBITDA | 127.9M | 26.4M | -19.3M | -54.6M | -11.3M | -28.3M | -68.4M | -72.1M | -79.2M | -68.8M |
| Interest expense | 7.32M | 7.92M | 6.87M | 3.71M | 4.86M | 1.35M | 335.0K | 0 | 0 | 0 |
| Income before tax | 121.8M | 18.4M | -25.1M | -58.6M | -17.3M | -29.7M | -66.9M | -70.5M | -78.0M | -69.2M |
| Income tax | -245.2M | 881.0K | 0 | 3.02M | 605.0K | 647.0K | -348.0K | 0 | 0 | 0 |
| Net income | 367.0M | 17.5M | -25.1M | -58.6M | -17.9M | -29.7M | -66.9M | -70.5M | -78.0M | -69.2M |
| Earnings per share, basic | 20.40 | 0.99 | -1.44 | -3.44 | -0.11 | -0.18 | -0.40 | -0.44 | -0.62 | -0.73 |
| Earnings per share, diluted | 19.48 | 0.99 | -1.44 | -3.44 | -0.11 | -0.18 | -0.40 | -0.44 | -0.62 | -0.73 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 40.6M | 56.7M | 32.8M | 24.5M | 18.9M | 30.4M | 22.5M | 76.3M | 38.3M | 17.6M |
| Short-term investments | 114.4M | 20.6M | 24.1M | 33.7M | 106.1M | 27.0M | 75.6M | 52.2M | 77.5M | 57.1M |
| Receivables | 51.8M | 41.6M | 30.6M | 40.3M | 15.5M | 16.0M | 10.1M | 4.08M | 0 | 0 |
| Inventory | 11.5M | 6.00M | 5.52M | 9.12M | 6.62M | 1.64M | 1.35M | 894.0K | 0 | 0 |
| Current assets | 240.2M | 135.1M | 99.3M | 115.9M | 154.5M | 89.0M | 119.0M | 137.0M | 117.4M | 76.2M |
| Property, plant and equipment | 30.0K | 92.0K | 165.0K | 857.0K | 2.18M | 2.68M | 2.16M | 1.39M | 875.0K | 1.16M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 513.6M | 164.0M | 117.2M | 134.3M | 167.3M | 110.4M | 147.6M | 139.1M | 119.1M | 78.1M |
| Accounts payable | 7.19M | 3.34M | 7.14M | 22.5M | 3.79M | 3.71M | 4.15M | 6.39M | 2.64M | 5.56M |
| Current liabilities | 99.2M | 63.3M | 53.3M | 65.2M | 63.6M | 40.8M | 58.2M | 27.7M | 18.3M | 22.6M |
| Long-term debt | 22.5M | 52.4M | 52.4M | 39.4M | 19.9M | 19.8M | 9.81M | 0 | 0 | |
| Total debt | 52.5M | 60.0M | 60.0M | 40.0M | 20.0M | 20.0M | 10.0M | 284.0K | 3.46M | |
| Total liabilities | 122.1M | 160.7M | 145.9M | 147.9M | 137.0M | 76.4M | 93.8M | 29.2M | 18.5M | 23.1M |
| Shareholders' equity | 391.5M | 3.29M | -28.6M | -13.6M | 30.4M | 34.0M | 53.8M | 109.9M | 100.6M | 55.0M |
| Shares outstanding | 18.3M | 17.7M | 17.5M | 173.4M | 171.6M | 169.3M | 168.0M | 167.2M | 146.8M | 99.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 75.7M | 31.5M | -5.74M | -73.8M | 5.88M | -52.2M | -41.5M | -58.8M | -77.6M | -75.9M |
| Capital spending | 0 | -396.0K | -15.0M | -450.0K | -627.0K | -1.26M | -1.46M | -1.11M | -164.0K | -804.0K |
| Free cash flow | 75.7M | 31.1M | -20.7M | -74.2M | 5.25M | -53.4M | -43.0M | -59.9M | -77.7M | -76.7M |
| Cash from investing | -92.4M | 4.13M | -4.30M | 72.8M | -80.0M | 47.5M | -23.7M | 25.0M | -19.5M | 24.9M |
| Cash from financing | 601.0K | -11.6M | 18.4M | 6.55M | 62.7M | 12.6M | 11.4M | 71.9M | 117.7M | 25.2M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 0 | -10.0M | 0 | 2.12M | 4.78M | 2.60M | 1.58M | 71.9M | 117.7M | 25.2M |
| Change in cash | -16.1M | 24.0M | 8.33M | 5.57M | -11.5M | 7.85M | -53.8M | 38.0M | 20.7M | -25.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 4, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 17, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 26, 2026 | Other filings | SEC |
| 8-K · Current report | May 20, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 21, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 3, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 3, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 3, 2026 | Results | SEC |
| 10-K · Annual report | Mar 3, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 3, 2026 | Management or board change | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 6, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 8-K · Current report | May 23, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 10, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 27, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 10, 2025 | Management or board change | SEC |
| 8-K · Current report | Mar 4, 2025 | Results | SEC |
| 10-K · Annual report | Mar 4, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Sep 19, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Aug 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 8, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 7, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 6, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| S-3 · Registration statement | Aug 2, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| 8-K · Current report | Jun 25, 2024 | Current report | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 8-K · Current report | May 29, 2024 | Management or board change | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Apr 12, 2024 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 10, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 29, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 29, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 5, 2024 | Results | SEC |
| 10-K · Annual report | Mar 5, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 22, 2024 | Acquisition or disposal | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 5, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 2, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 25, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2024 | Results | SEC |
| 8-K · Current report | Nov 30, 2023 | Current report | SEC |
| 8-K · Current report | Nov 7, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 7, 2023 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Aug 1, 2023 | Offer document | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Rigel Pharmaceuticals, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 18,829,972
- Fully diluted
- 18,829,972
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 18,829,972 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 18,829,972 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Stephen A. Sherwin Other companies: Biogen Inc. (Director · Since at least Mar 20, 2010); Neurocrine Biosciences, Inc. (Director · Since at least Jun 30, 2006); Epiphany Technology Acquisition Corp (Director · Sep 16, 2022 – Sep 16, 2022 · Past); BioPlus Acquisition Corp (Director · Dec 2, 2021 – Dec 2, 2021 · Past); Aduro Biotech Inc (Director · Jun 25, 2015 – May 5, 2020 · Past); Vical Incorporated (Director · May 23, 2013 – May 21, 2015 · Past); Verastem, Inc. (Director · Mar 5, 2013 – Jun 12, 2015 · Past); ANI Pharmaceuticals, Inc. (Director · Oct 14, 2009 – Mar 30, 2012 · Past); Cell Genesys Inc (Chairman and CEO, Director · Feb 7, 2006 – Oct 14, 2009 · Past) | Director · May 31, 2006 – May 11, 2016 · Past |
| Gary A. Lyons Other companies: Travere Therapeutics, Inc. (Director · Since at least Oct 8, 2014); Neurocrine Biosciences, Inc. (Director · Since at least May 25, 2010); Brickell Biotech Inc (Director · Feb 14, 2020 – May 17, 2022 · Past); Eledon Pharmaceuticals, Inc. (Director · May 10, 2017 – May 1, 2023 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); NeurogesX Inc (Director · Apr 27, 2011 – Jun 7, 2012 · Past); Vical Incorporated (Director · May 25, 2010 – May 23, 2018 · Past); Facet Biotech Corp (Director · Apr 20, 2010 – Apr 21, 2010 · Past) | Director · May 28, 2010 – May 26, 2023 · Past |
| Hollings Renton Other companies: AnaptysBio, Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least Jan 25, 2017); Zymeworks Inc. (Director · Jan 1, 2019 – Dec 7, 2023 · Past); Kythera Biopharmaceuticals Inc (Director · Dec 31, 2014 – Oct 1, 2015 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – Jul 2, 2020 · Past); Affymax Inc (Director · Jun 9, 2009 – Jun 13, 2012 · Past); Cepheid (Director · Apr 27, 2006 – Nov 4, 2016 · Past); Onyx Pharmaceuticals Inc (President and CEO, Director · Jan 19, 2006 – Feb 19, 2008 · Past) | Director · May 31, 2006 – May 15, 2013 · Past |
| Keith A. Katkin Other companies: Emergent BioSolutions Inc. (Independent Director · Since at least Apr 1, 2022); Eledon Pharmaceuticals, Inc. (Chairman of the Board of Directors · Since at least May 10, 2017); Syndax Pharmaceuticals, Inc. (Director · Since at least Mar 29, 2017); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Sep 26, 2018 – Feb 19, 2020 · Past); Carbylan Therapeutics Inc (Director · Apr 8, 2015 – Aug 3, 2015 · Past); Avanir Pharmaceuticals Inc (President and CEO, Director · May 15, 2013 – Dec 15, 2014 · Past) | Director · Jun 29, 2015 – May 19, 2021 · Past |
| Anthony Gregg Lapointe Other companies: Astria Therapeutics Inc (Director · Since at least Jan 3, 2019); Soligenix, Inc. (Director · Since at least Mar 10, 2009); Raptor Pharmaceutical Corp (Director · Jan 1, 2015 – Oct 24, 2016 · Past); Questcor Pharmaceuticals Inc (Director · Oct 9, 2009 – Jan 1, 2010 · Past); SciClone Pharmaceuticals Inc (Director · Mar 30, 2009 – Oct 13, 2017 · Past) | Director · Since at least Oct 31, 2017 |
| Michael P. Miller Other companies: BioXcel Therapeutics, Inc. (Director · Since at least Jul 1, 2022); Puma Biotechnology Inc (Director · Since at least Feb 23, 2018); Jazz Pharmaceuticals plc (EVP, US Commercial · Jul 31, 2014 – Mar 12, 2020 · Past); VIVUS Inc (Chief Commercial Officer · Apr 26, 2010 – Jan 25, 2013 · Past) | Director · Since at least Feb 1, 2026 |
| Jean Deleage Other companies: Raptor Pharmaceutical Corp (Director · Oct 3, 2006 – Jun 19, 2008 · Past); Idm Pharma Inc (Director · Jun 14, 2006 – Jun 14, 2007 · Past); Kosan Biosciences Inc (Director · May 5, 2006 – Jun 26, 2008 · Past) | Director · May 31, 2006 – May 28, 2010 · Past |
| Ryan Maynard Other companies: Foghorn Therapeutics Inc. (Chief Financial Officer · Since at least Feb 23, 2026); Iovance Biotherapeutics, Inc. (Director · Since at least Feb 16, 2015); Tvardi Therapeutics, Inc. (CHIEF FINANCIAL OFFICER · Sep 12, 2022 – Feb 8, 2024 · Past) | EVP & CFO · May 27, 2010 – Nov 3, 2017 · Past |
| Alison L Hannah Other companies: NeoGenomics, Inc. (Director · Since at least Jun 12, 2015); CytomX Therapeutics, Inc. (Chief Medical Officer · Feb 3, 2020 – Jul 19, 2022 · Past) | EVP, Chief Medical Officer · Since at least May 14, 2021 |
| Anne-Marie Duliege Other companies: ChemoCentryx Inc. (EVP, Chief of Strategic Dev. · Mar 25, 2014 – Nov 18, 2014 · Past); Affymax Inc (Chief Medical Officer · Jan 1, 2008 – Jan 30, 2013 · Past) | EVP & Chief Medical Officer · Mar 7, 2016 – Mar 20, 2019 · Past |
All 33 people
| Person | Seat |
|---|---|
| Jane Wasman Other companies: SELLAS Life Sciences Group, Inc. (Director · Since at least Dec 29, 2017); Acorda Therapeutics Inc (President, Intl and GC · Feb 9, 2006 – Dec 2, 2019 · Past) | Director · Since at least Apr 1, 2019 |
| Kamil Ali-Jackson Other companies: PDS Biotechnology Corporation (Director · Since at least Jun 15, 2021); Aclaris Therapeutics, Inc. (Chief Legal Officer · Dec 15, 2020 – Jan 3, 2022 · Past) | Director · Since at least Dec 16, 2021 |
| Mark W. Frohlich Other companies: Juno Therapeutics Inc (See Remarks · Dec 18, 2014 – Feb 29, 2016 · Past); Dendreon Corp (EVP, R&D and CMO · Apr 3, 2013 – Jan 20, 2014 · Past) | Director · Since at least Mar 6, 2025 |
| Peter S Ringrose Other companies: Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 30, 2019 · Past); Innoviva, Inc. (Director · Apr 27, 2010 – May 22, 2014 · Past) | Director · May 28, 2010 – May 17, 2018 · Past |
| Wolfgang Dummer Other companies: Alpine Immune Sciences Inc (Chief Medical Officer · Oct 2, 2023 – Oct 2, 2023 · Past); Aridis Pharmaceuticals Inc. (Chief Medical Officer · Aug 13, 2018 – Dec 5, 2018 · Past) | EVP & CMO · Nov 4, 2019 – Feb 2, 2023 · Past |
| Brian L Kotzin Other companies: Kyverna Therapeutics, Inc. (Director · Feb 7, 2024 – Feb 7, 2024 · Past) | Director · Aug 21, 2017 – May 25, 2024 · Past |
| Eldon C Mayer III Other companies: Eiger Biopharmaceuticals Inc (Ex VP & Chief Commerc. Officer · Jan 5, 2018 – Mar 17, 2023 · Past) | EVP & Chief Commercial Officer · Oct 10, 2016 – Nov 18, 2019 · Past |
| Gregg A. Lapointe Other companies: Soligenix, Inc. (Board Director · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
| James M Gower Other companies: Cell Genesys Inc (Director · Jun 30, 2006 – Oct 14, 2009 · Past) | CEO & Board Chairman, Director · Jan 25, 2006 – Feb 27, 2014 · Past |
| Stacy Markel Other companies: Nuvation Bio Inc. (Chief People Officer · Since at least Feb 10, 2021) | EVP Human Resources · Mar 19, 2018 – Mar 20, 2019 · Past |
| Bradford S Goodwin | Director · May 15, 2013 – May 19, 2021 · Past |
| David A Santos | EVP, Chief Commercial Officer · Since at least Jan 27, 2021 |
| Dean L Schorno | EVP & Chief Financial Officer · Since at least Jan 23, 2024 |
| Dolly Vance | EVP Corp. Affairs, G.C., Sect. · Mar 30, 2009 – Sep 14, 2022 · Past |
| Donald G Payan | EVP, Pres. Discovery&Research, Director · Apr 4, 2016 – Aug 30, 2016 · Past |
| Elliott B Grossbard | EVP, CMO · Jan 25, 2006 – Jan 26, 2016 · Past |
| Esteban Masuda | Sr. VP Research · Oct 10, 2016 – Nov 18, 2019 · Past |
| Joseph Lasaga | Sr.VP Bus.Dev.Alliance Mgmt. · Oct 10, 2016 – Nov 18, 2019 · Past |
| Lisa Rojkjaer | EVP, Chief Medical Officer · Since at least Mar 27, 2024 |
| Raul R. Rodriguez | President and Chief Executive Officer · Since at least Jan 26, 2016 |
| Raymond J Furey | EVP, GC, CCO & Corp Sec · Since at least Jan 23, 2024 |
| Robin D G Cooper | Sr. V.P. Pharmaceutical Scs. · Jan 25, 2006 – Jan 31, 2008 · Past |
| Walter H. Moos | Director · Since at least May 31, 2006 |
Log in to ask 6ix AI your own questions about Rigel Pharmaceuticals, Inc.